Phase I Study of Temozolomide and Irinotecan for Recurrent Malignant Gliomas in Patients Receiving Enzyme-Inducing Antiepileptic Drugs: A North American BrainTumor Consortium Study

PURPOSE: To determine the maximum tolerated dose of irinotecan when administrated with temozolomide every 28 days, in patients with recurrent malignant glioma who were also receiving CYP450 enzyme-inducing antiepileptic drugs (EIAED), and to characterize the pharmacokinetics of irinotecan and its me...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Loghin, Monica E., Prados, Michael D., Wen, Patrick, Junck, Larry, Lieberman, Frank, Fine, Howard, Fink, Karen L., Metha, Minesh, Kuhn, John, Lamborn, Kathleen, Chang, Susan M., Cloughesy, Timothy, DeAngelis, Lisa M., Robins, Ian H., Aldape, Kenneth D., AlfredYung, W.K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2007
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4802002/
https://ncbi.nlm.nih.gov/pubmed/18056194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-07-0874
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados